Caas Capital Management LP Cyteir Therapeutics, Inc. Transaction History

Caas Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$2.71 - $2.84 $22,658 - $23,745	-8,361 Reduced 24.21%	26,175 $74,000
Q2 2023 Aug 14, 2023	SELL	$1.74 - $2.6 $201,613 - $301,262	-115,870 Reduced 77.04%	34,536 $89,000
Q1 2023 May 15, 2023	SELL	$1.47 - $1.84 $454,778 - $569,246	-309,373 Reduced 67.29%	150,406 $273,000
Q4 2022 Feb 14, 2023	SELL	$1.18 - $1.76 $185,310 - $276,395	-157,043 Reduced 25.46%	459,779 $758,000
Q3 2022 Nov 14, 2022	BUY	$1.99 - $4.05 $1.07 Million - $2.17 Million	536,938 Added 672.15%	616,822 $1.27 Million
Q2 2022 Aug 15, 2022	SELL	$1.62 - $4.4 $40,835 - $110,910	-25,207 Reduced 23.99%	79,884 $239,000
Q1 2022 May 13, 2022	SELL	$3.39 - $10.51 $1.26 Million - $3.91 Million	-372,419 Reduced 77.99%	105,091 $396,000
Q4 2021 Feb 14, 2022	SELL	$9.83 - $19.21 $1 Million - $1.96 Million	-102,236 Reduced 17.63%	477,510 $5.43 Million
Q3 2021 Nov 15, 2021	BUY	$14.57 - $21.86 $1.16 Million - $1.74 Million	79,746 Added 15.95%	579,746 $10.2 Million
Q2 2021 Aug 16, 2021	BUY	$16.8 - $21.4 $8.4 Million - $10.7 Million	500,000 New	500,000 $10.7 Million

2.47M

Ticker CYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,413,400
Market Cap $107M
Description
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for c...

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Caas Capital Management LP with notifications on news.